A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
All content for The Life Challenges Podcast is the property of Christian Life Resources and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
BONUS EPISODE: Fearless Faith Conference: Building Courage in a Challenging World
The Life Challenges Podcast
10 minutes
2 months ago
BONUS EPISODE: Fearless Faith Conference: Building Courage in a Challenging World
Courage doesn't mean fearlessness—it means standing firm despite our fears. The upcoming Fearless Faith conference, hosted by Christian Life Resources on September 13th at Kettle Moraine Lutheran High School in Jackson, Wisconsin, offers exactly what today's Christians need: biblical wisdom for navigating our complex world. Based on Joshua 1:9, this one-day gathering brings together remarkable speakers who understand firsthand what it means to face life's storms with God's strength. From Pas...
The Life Challenges Podcast
A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
